Site Under Construction

A randomized, double-blind, controlled study on the safety and efficacy of 25% Tinospora rumphii (Makabuhay) cream versus 2% mupirocin cream on superficial pyodermas caused by Staphylococcus aureus (RITM)

Authors:Grace Monica Ibaviosa, MD, DPDS, Johannes Dayrit, MD, FPDS, Ma. Teresita G. Gabriel, MD, FPDS, Gracia B. Teodosio, MD, FPDS, Cara Lynn Chia, MD


BACKGROUND: Superficial pyoderma is an infection most commonly caused by Staphyloccoccus aureus. The drug of choice is 2% mupirocin cream. However, high cost and emerging drug resistance affect compliance and overall cure. Tinospora rumphii has demonstrated antibacterial activity in vivo rendering it a potential cost-effective alternative treatment.

OBJECTIVES: To determine the safety and efficacy of 25% T. rumphii cream versus 2% mupirocin cream in the treatment of superficial pyodermas caused by S. aureus.

METHODS: A randomized, double-blind, controlled study of 60 patients with superficial pyodermas caused by Saureus, aged 18-60, were given either 25% T. rumphii or 2% mupirocin cream for two weeks. Bactericidal activity, erythema, edema, induration and size of lesion were evaluated at baseline, days 3, 7, and 14. Participants Global Assessment (PGA) score and adverse events were noted. Statistical analysis was done using Mann-Whitney U and Pearson Chi square test. RESULTS: Fifty-one subjects (85%) completed the trial. There were no statistically significant differences between the two treatment groups for bactericial activity against Staphylococcus aureus (p=0.687) at day 14, for erythema (p=0.923, 0.5335, 0.3726, 0.6949), edema (p=0.0972, 0.5967, 0.2052, 0.2783), induration (p=0.0855, 0.3113, 0.281, 0.3161), and size of lesions (p=0.7262, 0.169, 0.15, 0.3988) at baseline, days 3, 7 and 14. There was no significant difference in PGA score (p=0.3086, 0.3483, 0.2234) at Days 3, 7 and 14 in both groups. No adverse events were noted.
CONCLUSION: Twenty five percent T. rumphii cream is equally safe and effective as 2% mupirocin cream for treatment of superficial pyodermas caused by S. aureus.


Tinospora rumphii, Mupirocin, Superficial pyoderma, Staphylococcus aureus

1. Kalshetti VT, Bhate VM, Haswani N, Bothikar ST. Staphylococcus aureus: a major causative agent of community- acquired pyoderma. Int.J.Curr. Microbiol.App.Sci (2014) 3(9) 94-97

2. Bowen AC, Mahe A, Hay RJ, Andrews RM, Steer AC, Tong ST, et al. The global epidemiology of impetigo: a systematic review of the population prevalence of impetigo and pyoderma. PLoS One 2015;10(8):e0136789

.3. Philippine Dermatological Society Health Information System. Internet. Available from

4. Gandhi S, Ojha SK, Ranjan KP, and Neelima. Clinical and Bacteriological Aspects of Pyoderma. N Am J Med Sci. 2012; 4(10): 492–495.

5. Ki V, Rotstein C. Bacterial skin and soft tissue infections in adults: A review of their epidemiology, pathogenesis, diagnosis, treatment and site of care. The Canadian Journal of Infectious Diseases & Medical Microbiology. 2008;19(2):173-184.

6. Templer J, Maximo SB. Bacterial Skin and Soft Tissue Infections. Curr Opin Infect Dis. 2009; 45(3): 9-16, 26

7. Tong, SYC, Davis, J, Eichenberger, E., Holland, T, Fowler VG. Staphylococcus Aureus Infections: Epidemiology, Pathophysiology, Clinical Manifestations, and Management. Clin Microbio Rev 2015: 603– 661

8. Chen, C.J, Huang, Y.C, New epidemiology of Staphylococcus aureus infection in Asia. Clinical Microbiology and Infection 2014: 20(17): 605-2

9. Davies J, Davies D. Origins and Evolution of Antibiotic Resistance. Microbio Mol Biol Rev 2010; 74(3): 417–433

10. Hetem, D.J., Bonten, M.J. Clinical relevance of mupirocin resistance in Staphylococcus aureus. J Hosp Infect. 2013; 85(4): 249-56

11. Gisby J, Bryant J. Efficacy of a New Cream Formulation of Mupirocin: Comparison with Oral and Topical Agents in Experimental Skin Infections. Antimicrobial Agents and Chemotherapy 2000; 44(2): 255- 260.

12. Eells L.D., Mertz P.M., Piovanetti Y., Pekoe G.M., Eaglstein W.H. Topical antibiotic treatment for impetigo with mupirocin. Arch Dermatol 1986; 122: 1273-6.

13. Breneman D.L. Use of mupirocin ointment in the treatment of secondarily infected dermatoses. J AM Acad Dermatol 1990; 22: 886-92.

14. Upton, A., Lang, S., Heffernan, H. Mupirocin and Staphylococcus aureus: a recent paradigm of emerging antibiotic resistance. Journal of Antimicrobial Chemotherapy. 2003;51:613-617

15. A.R. Caffrey, B.J. Quilliam, K.L. LaPlante, Risk factors associated with mupirocin resistance in meticillin-resistant Staphylococcus aureus, J Hosp Infect 2010; 76(3): 206-210

16. McNeil JC, Hulten KG, Kaplan SL, Mason EO. Mupirocin Resistance in Staphylococcus aureus Causing Recurrent Skin and Soft Tissue Infections in Children. Antimicrob Agents and Chemother. 2011;55(5):2431-2433

17. Lagda D, Sutantoyo CJ, Galang MC. In vitro evaluation of Makabuhay stem extract as an Antimicrobial Agent against Staphylococcus aureus Steptococcus pyogenes and Pseudomonas aeruginosa. 2015, Unpublished manuscript

18. Ahmad W, Jantan I, Bukhari SNA. Tinospora crispa (L.) Hook. f. & Thomson: A Review of Its Ethnobotanical, Phytochemical, and Pharmacological Aspects. Front Pharmacol. 2016;7:59

19. Tan RS, Bajo. LM. Modulation of Tinospora rumphii and zinc salt on DNA damage in quinoline-induced genotoxicity and hepatotoxicity in male albino mice. Advances in Toxicology. 2014

20. Castillo, A, Osi, MO, Ramos, JD, De Francia JL, Dujunco MU, Quilala, PF. Efficacy and safety of Tinospora cordifolia lotion in Sarcoptes scabiei var hominis-infected pediatric patients: A single blind, randomized controlled trial. J Pharmacol Pharmacother. 2013; 4(1):39-46

21. Dela Torre, LT, Ponsaran G, Ponsaran, MG, De Guzman, KD, De Guzman, LD, Manalo, AM, et al. Safety, efficacy, and physicochemical characterization of Tinospora crispa ointment: a community-based formulation against Pediculus humanus capitis. The Korean Journal of Parasitology. 2017; 55(4): 409-416

22. Hipol, R.L., Cariaga, M.F.N.M, and Hipol, R.M. Antiinflammatory activities of the aqueous extract of the stem of Tinospora crispa (Family Menispermaceae). Journal of Nature Sudies. 2012; 11(1&2): 88-95

23. Galia, MLD., Galia, J.D. Angiogenetic activity of Tinospora rumphii Boerl  (Makabuhay) Leaf and Stem Extracts. International Research Journal of Biological Sciences. 2016; 5(1): 54-59

24. Choudhary N, Siddiqui MB, Azmat S, Khatoon S. Tinospora cordifolia: Ethnobotany, Phytopharmacology and Phytochemistry Aspects. IJPSR, 2013; 4(3): 891-899.

25. Choudhary, MI, Ismail M, Ali, Z, Shaari K, Lajis NH, Atta-ur-Rhaman. Alkaloidal Constituents of Tinospora crispa. Nat Prod Commun. 2010;5(11):1747-50

26. Mohammed, AI. Antimicrobial activity of Tinospora crispa root extracts. International Journal of Research in Ayurveda and Pharmacy. May-June 2012 3(3):417-419

27. Ragasa, C, Cruz, MC. Antimicrobial Diterpenes from Tineaspora rumphii. Journal of Research Science, Computing and Engineering, 2005;2(1)

28. Sutantoyo CJ, Lagda D, , Dayrit JF, Gabriel, MT. An Evaluation of Rabbit Skin Irritation from Makabuhay Cream. 2016. Unpublished manuscript

29. Galang MC, Chia, CLN, , Gabriel, MT, Dayrit, JF, Teodosio, GB. Use of skin patch testing in determining safely of Tinospora rumphii 25%, 50%, 90% cream on normal skin. 2016. Unpublished manuscript

30. Panis L, Cejar R, Gabriel MT, Dayrit JF, A randomized, double-blind, controlled study on the safety and efficacy of 10% bee propolis ointment versus 2% superficial pyodermas caused by Staphylococcus aureus. 2014. Unpublished manuscript

31. Adasa, G, A Randomized, Double-blind, Controlled Study on the Safety and Efficacy of 2.5% Moringa oleifera Lam (Moringaceae) Leaf Extract Ointment versus 2% Mupirocin Ointment on Superficial Pyodermas caused by Staphylococcus aureus . Unpublished manuscript

32. Yusoff, M, Hamid, H, Houghton, P. Anticholinesterase inhibitory activity of quaternary alkaloids from Tinospora crispa. Molecules 2014; 19:1201-1211


More Articles


REquesting Permission

A randomized, double-blind, controlled study on the safety and efficacy of 25% Tinospora rumphii (Makabuhay) cream versus 2% mupirocin cream on superficial pyodermas caused by Staphylococcus aureus (RITM)